# Resource Summary Report

Generated by ASWG on Aug 9, 2026

## CD4 Monoclonal Antibody (OKT4 (OKT-4)), FITC, eBioscience

RRID:AB_1633390
Type: Antibody

### Proper Citation

(Thermo Fisher Scientific Cat# 11-0048-42, RRID:AB_1633390)

### Antibody Information

**URL:** http://antibodyregistry.org/AB_1633390

**Proper Citation:** (Thermo Fisher Scientific Cat# 11-0048-42, RRID:AB_1633390)

**Target Antigen:** CD4

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: Flow
Consolidation on 1/2020: AB_1633390, AB_10425846

**Antibody Name:** CD4 Monoclonal Antibody (OKT4 (OKT-4)), FITC, eBioscience

**Description:** This monoclonal targets CD4

**Target Organism:** human

**Clone ID:** Clone OKT4 (OKT-4)

**Antibody ID:** AB_1633390

**Vendor:** Thermo Fisher Scientific

**Catalog Number:** 11-0048-42

**Record Creation Time:** 20251213T073422+0000

**Record Last Update:** 20260225T230553+0000

### Ratings and Alerts

No rating or validation information has been found for CD4 Monoclonal Antibody (OKT4 (OKT-4)), FITC, eBioscience.

No alerts have been found for CD4 Monoclonal Antibody (OKT4 (OKT-4)), FITC, eBioscience.

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 9 mentions in open access literature.

**Listed below are recent publications.** The full list is available at ASWG .


Libri AB, et al. (2025) Senataxin promotes recombination fidelity during antigen receptor gene diversification. Science signaling, 18(908), eadv8801.

Swatler J, et al. (2024) Protocol for isolation of tumor-derived extracellular vesicles and functional studies on human T cell subsets. STAR protocols, 5(2), 103011.

Gao Y, et al. (2024) Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. Cancer cell, 42(10), 1764.

Chen C, et al. (2024) Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance. Cell reports. Medicine, 5(8), 101686.

Le Y, et al. (2024) VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors. iScience, 27(1), 108731.

Deng S, et al. (2024) ITPRIPL1 binds CD3? to impede T cell activation and enable tumor immune evasion. Cell, 187(9), 2305.

Si W, et al. (2023) Design of diversified chimeric antigen receptors through rational module recombination. iScience, 26(4), 106529.

Le Y, et al. (2022) NF-?B-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations. iScience, 25(11), 105426.

Ma X, et al. (2019) TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. eLife, 8.